# Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Source: https://onco.cc/trials/nct03733249/  
OnCo record `nct03733249` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, terminated.

## Summary

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study is a phase 1/2 interventional study registered as NCT03733249 by Bellicum Pharmaceuticals, with 187 participants enrolled, started 2017-01. Conditions recorded: Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immunodeficiency, Anemia, Aplastic, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia and Anemia, Sickle Cell. Interventions recorded: Rimiducid and rivogenlecleucel.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03733249
- Phase: 1/2
- Setting: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
- Sponsor: Bellicum Pharmaceuticals
- Enrolled: 187

## Sources

- ClinicalTrials.gov NCT03733249: https://clinicaltrials.gov/study/NCT03733249

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Rivogenlecleucel](https://onco.cc/drugs/rivogenlecleucel/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct03733249.json